AUPH Stock Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
Aurinia Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.65|
|52 Week High||US$33.97|
|52 Week Low||US$8.86|
|1 Month Change||4.48%|
|3 Month Change||-33.20%|
|1 Year Change||-9.13%|
|3 Year Change||78.41%|
|5 Year Change||76.78%|
|Change since IPO||468.29%|
Recent News & Updates
Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if Omicron variant doesn't resurge, then it's possible sales could improve further. Two presentations of results of AURORA-2 study using Lupkynis for LN expected end of May and in June of 2022; from there, manuscript of full results expected 2nd half of 2022. The global lupus nephritis market could reach $3.1 billion by 2027.
|AUPH||US Biotechs||US Market|
Return vs Industry: AUPH exceeded the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: AUPH exceeded the US Market which returned -11.5% over the past year.
|AUPH Average Weekly Movement||14.9%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: AUPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: AUPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Aurinia Pharmaceuticals Fundamentals Summary
|AUPH fundamental statistics|
Is AUPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AUPH income statement (TTM)|
|Cost of Revenue||US$55.23m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.19|
|Net Profit Margin||-253.66%|
How did AUPH perform over the long term?See historical performance and comparison
Is Aurinia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AUPH ($11.65) is trading below our estimate of fair value ($81.12)
Significantly Below Fair Value: AUPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AUPH is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AUPH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AUPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AUPH is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (1.5x).
How is Aurinia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AUPH's is expected to become profitable in the next 3 years.
Revenue vs Market: AUPH's revenue (41.4% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: AUPH's revenue (41.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AUPH's Return on Equity is forecast to be high in 3 years time
How has Aurinia Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUPH is currently unprofitable.
Growing Profit Margin: AUPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AUPH is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare AUPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: AUPH has a negative Return on Equity (-37.54%), as it is currently unprofitable.
How is Aurinia Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AUPH's short term assets ($477.6M) exceed its short term liabilities ($33.8M).
Long Term Liabilities: AUPH's short term assets ($477.6M) exceed its long term liabilities ($24.9M).
Debt to Equity History and Analysis
Debt Level: AUPH is debt free.
Reducing Debt: AUPH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AUPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AUPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AUPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AUPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AUPH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Greenleaf (51 yo)
Mr. Peter S. Greenleaf, M.B.A., has been President, Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019. Mr. Greenleaf has been a Director at Antares Pharma, Inc. sinc...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD1.24M) is below average for companies of similar size in the US market ($USD5.41M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: AUPH's management team is considered experienced (2.3 years average tenure).
Experienced Board: AUPH's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AUPH insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Aurinia Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Aurinia Pharmaceuticals Inc.
- Ticker: AUPH
- Exchange: NasdaqGM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.589b
- Shares outstanding: 141.74m
- Website: https://www.auriniapharma.com
Number of Employees
- Aurinia Pharmaceuticals Inc.
- 4464 Markham Street
- Suite 1203
- British Columbia
- V8Z 7X8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.